Thermo Fisher Scientific (NYSE:TMO) announced today that completed its previously announced acquisition of Mesa Biotech.
Last month, Waltham, Mass.-based Thermo Fisher announced its agreement to buy the point-of-care molecular diagnostic developer for approximately $450 million in cash. Mesa Biotech will become part of Thermo Fisher’s life sciences solution segment and is expected to bring in revenue of approximately $200 million in 2021, according to a news release.
The San Diego-based company has approximately 500 employees and revenues in 2020 of approximately $45 million.
Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones as well.
Mesa Biotech develops the Accula system for point-of-care PCR-based testing for infectious disease diagnoses. The affordable, easy-to-use platform enables rapid, accurate testing at physician offices, pharmacies and other s…